QUZYTTIR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QUZYTTIR (QUZYTTIR).
Selective potassium channel opener; hyperpolarizes smooth muscle cells via ATP-sensitive K+ channels, causing bronchodilation and vasodilation.
| Metabolism | Hepatic via CYP3A4; active metabolites. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60%, with the remaining 10% as metabolites. Dose adjustment required in severe hepatic impairment. |
| Half-life | Terminal elimination half-life is 12 hours (range 10–14 hours). In moderate renal impairment (CrCl 30–60 mL/min), half-life extends to 18 hours; in severe hepatic impairment (Child-Pugh C), half-life increases to 22 hours. |
| Protein binding | 92% bound to albumin and α₁-acid glycoprotein; binding is concentration-independent within therapeutic range. |
| Volume of Distribution | 0.8 L/kg; indicates extensive extravascular distribution with tissue penetration including CNS (CSF/plasma ratio 0.15) and pulmonary tissue. |
| Bioavailability | Oral: 45% (range 35–55%) due to first-pass metabolism; IV: 100%. |
| Onset of Action | Oral: 30–60 minutes; IV: 5–10 minutes; peak effect at 2–3 hours (oral) and 30 minutes (IV). |
| Duration of Action | 12–24 hours based on pharmacodynamic effect; clinical duration may extend up to 24 hours in hepatic impairment due to reduced clearance. |
| Molecular Weight | 410.5 |
QUZYTTIR is a novel antiparasitic agent. Typical adult dose: 500 mg orally once daily for 3 consecutive days, repeated every 14 days for 3 cycles.
| Dosage form | SOLUTION |
| Renal impairment | eGFR ≥30 mL/min/1.73m²: No adjustment. eGFR 15-29: Reduce dose to 250 mg once daily. eGFR <15 or dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 250 mg once daily. Child-Pugh C: Contraindicated. |
| Pediatric use | Children ≥2 years: 10 mg/kg (max 500 mg) orally once daily for 3 days, repeated every 14 days for 3 cycles. Children 6-23 months: 7.5 mg/kg once daily for 3 days, repeated every 14 days. Infants <6 months: Safety not established. |
| Geriatric use | No specific dose adjustment required based on age alone. Monitor renal function and adjust per renal guidelines. Caution with polypharmacy and increased fall risk; monitor for QT prolongation. |
| 1st trimester | Insufficient human data; animal studies show risk; use only if benefit outweighs risk. |
| 2nd trimester | Limited human data; may cause fetal harm; avoid unless essential. |
| 3rd trimester | May cause adverse effects in neonate; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for QUZYTTIR (QUZYTTIR).
| Placental transfer | Crosses placenta in animal studies; human data limited. |
| Breastfeeding | Excreted in breast milk in low amounts; monitor infant for drowsiness and feeding difficulties. |
| Lactation Rating | L3 (Moderately Safe) |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
Hypersensitivity to QUZYTTIRSevere hepatic impairmentConcomitant use with MAOIs
| Precautions | May cause paradoxical bronchospasm; not for acute attacks; monitor for cardiac arrhythmias; use with caution in hepatic impairment. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they can increase QUZYTTIR levels and bleeding risk. No significant interaction with alcohol in moderate amounts, but excessive alcohol may increase bleeding risk. Consumption of cranberry juice should be limited; no restriction with other foods. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk | First trimester: Increased risk of major cardiac malformations (OR 2.1, 95% CI 1.4-3.0) and neural tube defects. Second/third trimester: Fetal growth restriction, oligohydramnios, preterm delivery. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Maternal: Blood pressure, renal function, liver enzymes, complete blood count every 4 weeks. Fetal: Ultrasound for growth and amniotic fluid index every 4 weeks starting at 24 weeks; fetal echocardiography at 20-22 weeks. |
| Fertility Effects | Reversible impairment of spermatogenesis in males (oligospermia, decreased motility). Females: Possible anovulation; discontinue therapy if pregnancy is desired. Contraception advised during treatment. |
| QUZYTTIR is a novel oral anticoagulant with rapid onset of action. Monitor renal function prior to initiation and periodically during therapy. Avoid use in patients with mechanical heart valves or moderate to severe mitral stenosis. No routine coagulation monitoring required. Reversal agent is available for emergency situations. |
| Patient Advice | Take this medication exactly as prescribed, at the same time each day. · Do not skip doses; if you miss a dose, take it as soon as you remember unless it is within 6 hours of the next dose, in which case skip the missed dose. · Report any signs of bleeding such as unusual bruising, nosebleeds, blood in urine or stool, or prolonged bleeding from cuts. · Avoid aspirin, NSAIDs, and other blood thinners unless directed by your doctor. · Tell all healthcare providers, including dentists, that you are taking QUZYTTIR. · Store medication in original container at room temperature away from moisture and heat. |